basically metabolic syndrome is HEART DISEASE. As you’d imagine the market for metabolic is huge. (the biggest but for cancer)
(think of all the food products that utilise omega 3, fish oils, dietary/medical supplements etc.. the nutriceutical foods market is the second fastest biotech market globally)
this deal is for the medical nutrition side of nestle's business ie hospital and GP prescription etc. The really significant (read billion dollar) bits are for the foods divisions (nestle are the BIGGEST food company in the world).
Once the market realises that:
POH are commercialising their Phosphorilated E for use in a range of the Nestlé’s medical food products plus the strong likelihood of their basic food products as well as manufacturing and supplying the Phosphorilated Vit E it will take notice.
That Nestlé have signed on only reinforces the likelihood others will follow.
This is a billion dollar market. AND just one of POH’s very prospective lines.
My opinion only.
POH Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)